Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Free Cash Flow (2017 - 2025)

Crinetics Pharmaceuticals (CRNX) has 9 years of Free Cash Flow data on record, last reported at -$93.4 million in Q4 2025.

  • For Q4 2025, Free Cash Flow fell 45.34% year-over-year to -$93.4 million; the TTM value through Dec 2025 reached -$383.7 million, down 66.55%, while the annual FY2025 figure was -$383.7 million, 66.55% down from the prior year.
  • Free Cash Flow reached -$93.4 million in Q4 2025 per CRNX's latest filing, up from -$115.9 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$13.6 million in Q1 2022 and bottomed at -$115.9 million in Q3 2025.
  • Average Free Cash Flow over 5 years is -$49.5 million, with a median of -$41.4 million recorded in 2023.
  • Peak YoY movement for Free Cash Flow: surged 32.15% in 2022, then plummeted 198.86% in 2023.
  • A 5-year view of Free Cash Flow shows it stood at -$22.6 million in 2021, then plummeted by 62.77% to -$36.8 million in 2022, then decreased by 12.09% to -$41.3 million in 2023, then crashed by 55.72% to -$64.2 million in 2024, then tumbled by 45.34% to -$93.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were -$93.4 million in Q4 2025, -$115.9 million in Q3 2025, and -$85.7 million in Q2 2025.